What does A1C reduction mean? It usually means average blood sugar has fallen. A1C, also written HbA1c, is a blood test that reflects average blood sugar over about three months. A drop from 8% to 7% is one percentage point, worth about 29 mg/dL in estimated average blood sugar. That's the unit on many U.S. glucose meters.
The drop matters, but so do the starting number, the time involved and whether treatment causes low blood sugar.
What does A1C reduction mean in blood sugar units?
A1C is printed as a percentage. The percentage measures how much of the oxygen-carrying protein in red blood cells has sugar attached. It isn't the same measurement as a finger-stick reading.
The ADAG study, which compared A1C with thousands of glucose readings in 507 adults, supplied a translation. Its formula is estimated average glucose = 28.7 × A1C − 46.7, in mg/dL (Nathan and colleagues, Diabetes Care, 2008). Estimated average glucose is often shortened to eAG.
| A1C on the report | Calculated eAG, rounded |
|---|---|
| 9% | 212 mg/dL |
| 8% | 183 mg/dL |
| 7% | 154 mg/dL |
| 6.5% | 140 mg/dL |
So 8% to 7% means roughly 183 to 154 mg/dL. A half-point drop, from 7% to 6.5%, means about 14 mg/dL less. These are estimates from the formula, not readings measured on a particular person's meter.
A one-point drop is subtraction. A relative reduction expresses the change as a share of the starting A1C. From 8% to 7%, A1C falls one point, or 12.5% relative to its start.
Tirzepatide A1C reduction, translated
Semaglutide acts on the receptor for GLP-1, a gut hormone involved in blood sugar and appetite; tirzepatide acts on both the GLP-1 and GIP receptors.
SURPASS-2 compared tirzepatide with semaglutide 1 mg for 40 weeks in 1,879 adults with type 2 diabetes. Starting A1C averaged 8.28%. The paper's headline results were these group averages (Frías and colleagues, New England Journal of Medicine, 2021):
| Weekly study treatment | A1C drop, percentage points | Calculated eAG decrease |
|---|---|---|
| Tirzepatide 5 mg | 2.01 | About 58 mg/dL |
| Tirzepatide 10 mg | 2.24 | About 64 mg/dL |
| Tirzepatide 15 mg | 2.30 | About 66 mg/dL |
| Semaglutide 1 mg | 1.86 | About 53 mg/dL |
The last column translates A1C using ADAG; the trial didn't measure those figures as a separate outcome. The extra A1C drop over semaglutide was 0.15 to 0.45 points. The doses were trial assignments. A prescriber sets the dose for an individual prescription.
What a 1-point A1C drop meant for complications
UKPDS 35 looked at long-term blood sugar and complications in people with type 2 diabetes. Its risk analysis included 3,642 people. Relative risk compares the chance of an event between groups. Each one-point lower average A1C over time was associated with these reductions (Stratton and colleagues, BMJ, 2000):
| Outcome | Lower relative risk per point |
|---|---|
| Small-vessel complications, mainly eye treatment | 37% |
| Heart attack | 14% |
| Any diabetes-related outcome | 21% |
| Diabetes-related death | 21% |
A 37% reduction doesn't mean 37 of every 100 people avoid a complication.
UKPDS 35 was observational: it followed people over time. It didn't assign a one-point fall or test semaglutide or tirzepatide. These associations cannot predict a person's benefit from one lower test result.
How much does Ozempic lower A1C?
Ozempic contains semaglutide. Its SUSTAIN trials show why the starting point and other medicines matter. Two 30-week trials reported average drops of about 1.4 to 1.8 points at the doses below. Placebo means a look-alike injection without the study drug.
| Trial | Starting A1C | Semaglutide 0.5 mg | Semaglutide 1 mg | Placebo drop |
|---|---|---|---|---|
| SUSTAIN 1 | 8.05% | 1.45 points | 1.55 points | 0.02 points |
| SUSTAIN 5 | 8.4% | 1.4 points | 1.8 points | 0.1 points |
SUSTAIN 1 enrolled adults managing diabetes with diet and exercise alone (Sorli and colleagues, Lancet Diabetes & Endocrinology, 2017). SUSTAIN 5 added semaglutide to basal insulin, the background insulin that works between meals and overnight (Rodbard and colleagues, Journal of Clinical Endocrinology & Metabolism, 2018).
These aren't two estimates for the same situation. The participants, starting blood sugar and background treatment differed. The larger drop in one group doesn't establish what another person will get.
What today's bigger A1C headline leaves out
As of September 30, 2026, the day this article was written, Lilly had reported results from a 48-week trial of EloraTZP, a combination of eloralintide and tirzepatide still being tested. In 367 adults with excess weight and type 2 diabetes, its highest combination dose showed a 2.9-point A1C drop, versus 2.4 with tirzepatide 15 mg alone (Lilly's September 30 release).
Those figures estimate results assuming participants stayed on treatment throughout. About 11 to 27 in 100 people in the combination groups stopped because of side effects, versus about 3 in 100 on tirzepatide. This is a company announcement from a mid-stage trial; the combination remains investigational. A bigger A1C number alone doesn't settle the treatment choice.
A1C 7% vs 6.5%: which is the target?
As of September 30, 2026, the day this article was written, the American Diabetes Association (ADA) 2026 Standards of Care supported under 7% for many nonpregnant adults without serious or disruptive low blood sugar. Below 6.5% may suit people in good health with low treatment risks and burdens. Frailty or complex illness may call for a less demanding goal.
The target is chosen with the prescriber. It isn't a contest to reach the lowest percentage.
When the average misses something
A1C can hide highs and lows. A continuous glucose monitor, a sensor that tracks glucose throughout the day, helps show those swings. Anemia, meaning too few healthy red blood cells, and recent transfusions can also distort A1C (NIDDK's A1C explanation).
A lower result alongside repeated lows needs review. Your prescriber may adjust diabetes medicines, especially insulin or sulfonylureas, medicines that stimulate insulin release. The same ADA guidance supports assessing glucose readings alongside A1C.
What these numbers mean for a prescribed formulation
The medicine trials above studied manufacturer products. Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, prepared by a pharmacy for a prescription. That is different from an FDA-approved product: the formulations offered here are not FDA-approved. Those trial averages don't establish the results of a compounded preparation.
As of September 30, 2026, the day this article was written, the FDA says it doesn't verify compounded drugs' safety, effectiveness or quality before marketing. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
The numbers that belong in the visit
The useful comparison includes the previous A1C, the new result, their dates, current medicines and any low readings. That gives the prescriber more to work with than a percentage alone.
Blood pressure and weight have their own measurements, covered in semaglutide and blood pressure and what 10 percent weight loss looks like. One improving number doesn't answer every health question.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
